The LITE program supports the development of new therapies targeting LRRK2 for the treatment of Parkinson's disease patients, including Seal Rock Therapeutics' brain-penetrant LRRK2/ASK1 signaling complex (LASC) inhibitors.
A team of researchers at the University of California, San Francisco has developed a data-driven method for optimizing deep brain stimulation (DBS) settings that significantly improved walking performance in people with Parkinson’s disease.
Parkinson's DiseaseSociety of the United Kingdom published this content on August 11, 2025, and is solely responsible for the information contained herein.
For people living with Parkinson's disease in west-central Illinois and beyond, letting the neurodegenerative illness beat them simply is not an option ... .
(MENAFN - EIN Presswire) Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8.1% CAGR, driven by novel ... .
Parkinson's DiseaseSociety of the United Kingdom published this content on July 28, 2025, and is solely responsible for the information contained herein.
Parkinson's DiseaseSociety of the United Kingdom published this content on July 25, 2025, and is solely responsible for the information contained herein.
In GBA1Parkinson's disease, GCase deficiency leads to the accumulation of α-synuclein and subsequent death of neuronal cells that are hallmarks of Parkinson's. The MJFF grant will support the ...
Black Sabbath star Ozzy Osbourne died at 76, five years after he was diagnosed with Parkinson's disease - a condition which has a range of symptoms that people should be aware of ... .